BMI View: Pharmaceutical companies operating in Finland will continue to be targets of cost-containment
policies and experience more price erosions and generic competition. However, the country will remain
attractive to multinational drugmakers due to its excellent re ..."
BMI View: The excellent regulatory environment, ageing population, preference for patented medicines
and encouraging macroeconomic growth prospects will provide stable revenue-generating opportunities for
multinational pharmaceutical companies. However, the pharmaceut ..."
BMI View: We anticipate further price erosions mechanisms will be introduced to the Finnish pharmaceutical market. Mimicking the strategy adopted by governments across Europe, Finland has identified the pharmaceuticals industry as a focus for cost containment, due to the relative ..."
BMI View: The Finnish government's focus on drug pricing will significantly constrict drugmakers'
revenue-earning opportunities in 2013. In addition to the introduction of a reference price system in 2009,
which led to a sharp drop in drug prices and consequently hit companies ..."
OVERVIEW OF THE PHARMACEUTICAL MARKET IN FINLAND
The macroenvironment for the Finnish pharmaceutical industry is improving. Politically, the new six-party coalition is larger and represents a broader spectrum of opinion than is usual, which could make it unstable. However, the ..."
BMI View: While Finland''s pharmaceutical market is small compared with its Western European neighbours, BMI believes the country''s high public expenditure on health and its favourable business environment are major factors in making it an attractive place for medicine sales. Ho ..."